HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

XUANZHUBIO-B

11.060

-0.040-0.36%

Volume:301.00K

Turnover:3.34M

Market Cap:5.73B

PE:-17.88

High:11.500

Open:11.500

Low:11.000

Close:11.100

52wk High:96.900

52wk Low:10.600

Shares:518.00M

HK Float Shares:517.95M

Volume Ratio:0.94

T/O Rate:0.06%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-0.618

ROE:-21.10%

ROA:-10.28%

PB:3.58

PE(LYR):-17.88

PS:94.83

Loading ...

Overview Company News Filings

We're Not Very Worried About Xuanzhu Biopharmaceutical's (HKG:2575) Cash Burn Rate

Simply Wall St.

Xuanzhu Biopharmaceutical Sets Board Meeting to Review Interim Results

Xuanzhu Biopharma Ordered to Pay RMB 9.33 Million in Cietac Arbitration Award

Xuanzhu Biopharm Maintains 517.95 Million H-Share Capital in June; Public Float Meets 24.96% Requirement

Bulletin Express

XUANZHUBIO-B gains NMPA NDA acceptance for Anaprazole Sodium to treat reflux esophagitis

Bulletin Express

Xuanzhu Biopharma Says NMPA Accepts NDA for Anaprazole Sodium in Reflux Esophagitis

Xuanzhu Biopharmaceutical Co - Nmpa Accepts Nda for Anaprazole Sodium for Reflux Esophagitis

THOMSON REUTERS

Xuanzhu Biopharmaceutical Co - Phase Iii Trial for Anaprazole Sodium Met Primary Endpoint with 88.4% Healing Rate

THOMSON REUTERS

Xuanzhu Biopharmaceutical Enrolls First Patient in Anaprazole Sodium Study

MT Newswires Live

Four Hong Kong-listed Companies Launch IPO Processes, Including Medical Robotics Firm, While Able Digital Inks Major Partnership with Alibaba Cloud

Xuanzhu Bio-B Initiates Phase III Trial for H. Pylori Eradication with New Anaprazole Sodium Indication

Xuanzhu Biopharma enrolls first patient in Phase III trial of anaprazole sodium for H. pylori eradication

XUANZHUBIO-B Announces Election of Employee Representative Director

Xuanzhu Biopharmaceutical Tightens Governance Framework in Revised Articles; Confirms 9-Member Board and HK$517.95 Million Share Capital

Bulletin Express

Xuanzhu Biopharmaceutical files director list with Hong Kong Stock Exchange

Xuanzhu Biopharma names Yue Xin employee representative director after election

Xuanzhu Bio Converts 357.25 Million Unlisted Shares to H Shares, Expanding Total Issued Capital to 517.95 Million

Bulletin Express

XUANZHUBIO-B Shares Surge as Three Key Products Advance to Commercial Stage

Xuanzhu Biopharma to Seek Shareholder Nod on 2025 Reports, Profit Distribution and Board Mandates at 18 June 2026 AGM

Bulletin Express

Xuanzhu Biopharmaceutical announces annual general meeting

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/02575/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02575","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02575\",,,,,undefined,":{"symbol":"02575","market":"HK","secType":"STK","nameCN":"XUANZHUBIO-B","latestPrice":11.06,"timestamp":1787299687045,"preClose":11.1,"halted":0,"volume":301000,"delay":0,"changeRate":-0.003603603603603527,"floatShares":517947790,"shares":518000000,"eps":-0.6184503916756189,"marketStatus":"Market Closed","change":-0.04,"latestTime":"08-21 16:08:07","open":11.5,"high":11.5,"low":11,"amount":3344475,"amplitude":0.045045,"askPrice":11.19,"askSize":500,"bidPrice":11.06,"bidSize":500,"shortable":3,"etf":0,"ttmEps":-0.6126159540183017,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1787535000000},"marketStatusCode":7,"adr":0,"listingDate":1760457600000,"exchange":"SEHK","adjPreClose":11.1,"openAndCloseTimeList":[[1787275800000,1787284800000],[1787288400000,1787299200000]],"volumeRatio":0.9356386313369379,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02575\",,,,,undefined,":{"symbol":"02575","floatShares":517947790,"roa":"-10.28%","roe":"-21.10%","lyrEps":-0.61845,"volumeRatio":0.9356386313369379,"shares":518000000,"dividePrice":0,"high":11.5,"amplitude":0.045045,"preClose":11.1,"low":11,"week52Low":10.6,"pbRate":"3.58","psRate":"94.83","week52High":96.9,"institutionHeld":0,"latestPrice":11.06,"eps":-0.6184503916756189,"divideRate":0,"volume":301000,"delay":0,"ttmEps":-0.6126159540183017,"open":11.5,"prevYearClose":70.5,"prevWeekClose":12.36,"prevMonthClose":10.99,"prevQuarterClose":13.33,"fiveDayClose":12.36,"twentyDayClose":11.74,"sixtyDayClose":15.9,"earningDate":1787673600000},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02575\",params:#limit:5,,,undefined,":[{"date":"2026-08-26","symbol":"02575","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787707800000,"name":null,"time":"","dateTimestamp":1787673600000,"actualEps":null},{"date":"2026-03-30","symbol":"02575","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774834200000,"name":null,"time":"","dateTimestamp":1774800000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02575\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02575\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02575\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02575","date":"2026-08-21","current":-18.053725,"percent":0.990338,"low":-70.039607,"twenty":-55.365612,"median":-44.352491,"eighty":-26.122142,"high":-19.464395,"avg":-42.309546,"sd":14.005498,"marketCap":5728502557},"quantilePoints":[{"date":"2025-10-17","current":-28.93414,"twenty":-27.261252,"median":-24.751919,"eighty":-23.367582,"marketCap":17558430081},{"date":"2025-10-24","current":-50.850969,"twenty":-50.816841,"median":-33.923646,"eighty":-26.424807,"marketCap":30869688284},{"date":"2025-10-31","current":-54.182971,"twenty":-53.663557,"median":-50.808309,"eighty":-28.95487,"marketCap":32941479444},{"date":"2025-11-07","current":-55.367666,"twenty":-55.639174,"median":-53.630543,"eighty":-30.992132,"marketCap":33640708960},{"date":"2025-11-14","current":-54.36116,"twenty":-55.639174,"median":-54.1994,"eighty":-41.200731,"marketCap":33122761170},{"date":"2025-11-21","current":-53.748657,"twenty":-55.319259,"median":-54.136108,"eighty":-50.782713,"marketCap":32734300328},{"date":"2025-11-28","current":-53.384655,"twenty":-55.070724,"median":-54.15954,"eighty":-50.923112,"marketCap":32630710770},{"date":"2025-12-05","current":-54.773392,"twenty":-55.070724,"median":-54.21583,"eighty":-51.627953,"marketCap":33537119402},{"date":"2025-12-12","current":-70.039607,"twenty":-55.665823,"median":-54.261136,"eighty":-53.311356,"marketCap":42963769180},{"date":"2025-12-19","current":-60.019152,"twenty":-56.570931,"median":-54.488669,"eighty":-53.433833,"marketCap":36903780037},{"date":"2025-12-24","current":-59.160975,"twenty":-59.157371,"median":-54.549256,"eighty":-53.581365,"marketCap":36489421805},{"date":"2026-01-02","current":-54.537602,"twenty":-59.158272,"median":-54.690337,"eighty":-53.655303,"marketCap":33770195908},{"date":"2026-01-09","current":-52.983682,"twenty":-59.049917,"median":-54.49123,"eighty":-52.274882,"marketCap":32889684665},{"date":"2026-01-16","current":-58.758617,"twenty":-58.846722,"median":-54.572443,"eighty":-53.169291,"marketCap":36593011363},{"date":"2026-01-23","current":-52.071916,"twenty":-58.705513,"median":-54.4959,"eighty":-52.506318,"marketCap":32397634264},{"date":"2026-01-30","current":-53.326607,"twenty":-57.909955,"median":-54.48995,"eighty":-52.506318,"marketCap":33329940286},{"date":"2026-02-06","current":-57.283358,"twenty":-57.848985,"median":-54.4959,"eighty":-52.506318,"marketCap":35893781847},{"date":"2026-02-13","current":-51.942748,"twenty":-58.578655,"median":-54.516751,"eighty":-52.506318,"marketCap":32734300328},{"date":"2026-02-20","current":-51.153455,"twenty":-58.517685,"median":-54.493565,"eighty":-52.321662,"marketCap":32190455148},{"date":"2026-02-27","current":-53.732962,"twenty":-57.403185,"median":-54.403912,"eighty":-52.138331,"marketCap":34184554140},{"date":"2026-03-06","current":-41.037619,"twenty":-57.295346,"median":-54.261136,"eighty":-51.687579,"marketCap":25897389500},{"date":"2026-03-13","current":-40.849477,"twenty":-57.283358,"median":-54.21583,"eighty":-50.904735,"marketCap":25897389500},{"date":"2026-03-20","current":-35.26408,"twenty":-56.603099,"median":-54.112473,"eighty":-49.228933,"marketCap":22271754970},{"date":"2026-03-27","current":-28.858752,"twenty":-56.47148,"median":-53.935449,"eighty":-43.741043,"marketCap":18179967429},{"date":"2026-04-02","current":-57.594339,"twenty":-56.497804,"median":-53.833069,"eighty":-43.169536,"marketCap":16087458357},{"date":"2026-04-10","current":-59.545661,"twenty":-57.25627,"median":-53.970491,"eighty":-43.400861,"marketCap":16760790484},{"date":"2026-04-17","current":-61.727863,"twenty":-57.517877,"median":-54.136108,"eighty":-43.645588,"marketCap":17382327832},{"date":"2026-04-24","current":-45.649544,"twenty":-57.360049,"median":-54.047185,"eighty":-44.053945,"marketCap":12855464147},{"date":"2026-04-30","current":-39.643505,"twenty":-57.292948,"median":-53.884259,"eighty":-43.829171,"marketCap":11166954352},{"date":"2026-05-08","current":-39.029961,"twenty":-57.269814,"median":-53.732962,"eighty":-42.509315,"marketCap":11032287927},{"date":"2026-05-15","current":-34.724128,"twenty":-57.211578,"median":-53.651177,"eighty":-40.906347,"marketCap":9841008010},{"date":"2026-05-22","current":-32.788719,"twenty":-57.162996,"median":-53.511235,"eighty":-40.250137,"marketCap":9271265441},{"date":"2026-05-29","current":-29.882198,"twenty":-57.033621,"median":-53.326607,"eighty":-39.029961,"marketCap":8478805322},{"date":"2026-06-05","current":-31.916861,"twenty":-56.603099,"median":-53.185623,"eighty":-36.605471,"marketCap":9069265802},{"date":"2026-06-12","current":-29.603728,"twenty":-56.47148,"median":-52.629422,"eighty":-35.26408,"marketCap":8406292631},{"date":"2026-06-18","current":-30.479088,"twenty":-56.448102,"median":-52.321662,"eighty":-34.687576,"marketCap":8675625482},{"date":"2026-06-26","current":-23.369212,"twenty":-56.068362,"median":-52.035899,"eighty":-32.252252,"marketCap":6619372756},{"date":"2026-07-03","current":-26.037742,"twenty":-55.925853,"median":-51.815163,"eighty":-31.259875,"marketCap":7380756007},{"date":"2026-07-10","current":-23.563382,"twenty":-55.788956,"median":-51.211683,"eighty":-30.461424,"marketCap":6671167535},{"date":"2026-07-17","current":-22.969392,"twenty":-55.712025,"median":-50.877852,"eighty":-29.911789,"marketCap":6526142154},{"date":"2026-07-24","current":-21.396832,"twenty":-55.583366,"median":-50.208288,"eighty":-29.704477,"marketCap":6080707054},{"date":"2026-07-31","current":-19.991935,"twenty":-55.489987,"median":-48.334812,"eighty":-29.33959,"marketCap":5692246212},{"date":"2026-08-07","current":-22.658402,"twenty":-55.433258,"median":-45.681548,"eighty":-28.96324,"marketCap":6463988419},{"date":"2026-08-14","current":-22.412159,"twenty":-55.37071,"median":-44.835824,"eighty":-28.336789,"marketCap":6401834684},{"date":"2026-08-21","current":-20.01067,"twenty":-55.365612,"median":-44.352491,"eighty":-26.122142,"marketCap":5728502557}],"updateTime":1787455963506},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02575\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2660479250","title":"We're Not Very Worried About Xuanzhu Biopharmaceutical's (HKG:2575) Cash Burn Rate","url":"https://stock-news.laohu8.com/highlight/detail?id=2660479250","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660479250?lang=en_us&edition=fundamental","pubTime":"2026-08-20 06:56","pubTimestamp":1787180214,"startTime":"0","endTime":"0","summary":"There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2575/xuanzhu-biopharmaceutical-shares/news/were-not-very-worried-about-xuanzhu-biopharmaceuticals-hkg25","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2575/xuanzhu-biopharmaceutical-shares/news/were-not-very-worried-about-xuanzhu-biopharmaceuticals-hkg25","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["02575","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659155279","title":"Xuanzhu Biopharmaceutical Sets Board Meeting to Review Interim Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2659155279","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659155279?lang=en_us&edition=fundamental","pubTime":"2026-08-13 18:57","pubTimestamp":1786618663,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharmaceutical sets board meeting to review interim resultsXuanzhu Biopharmaceutical will hold a board meeting on Aug. 26, 2026.Directors will review interim results for the six months ende","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nNDL3w6dBz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","00460","BK1600","02575","BK1191","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652377251","title":"Xuanzhu Biopharma Ordered to Pay RMB 9.33 Million in Cietac Arbitration Award","url":"https://stock-news.laohu8.com/highlight/detail?id=2652377251","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652377251?lang=en_us&edition=fundamental","pubTime":"2026-07-19 18:49","pubTimestamp":1784458150,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharma ordered to pay RMB 9.33 million in CIETAC arbitration awardXuanzhu Biopharmaceutical received a final CIETAC arbitration award on July 15, 2026 over a May 21, 2021 technology transfe","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260719:nNDL9lltbr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1593","BK1600","00460","02575","BK1515","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126665105","title":"Xuanzhu Biopharm Maintains 517.95 Million H-Share Capital in June; Public Float Meets 24.96% Requirement","url":"https://stock-news.laohu8.com/highlight/detail?id=1126665105","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1126665105?lang=en_us&edition=fundamental","pubTime":"2026-07-07 17:06","pubTimestamp":1783415163,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharmaceutical Co., Ltd. reported no movements in share capital during June 2026. Issued H shares remained at 517.95 million, each with a par value of RMB 1, keeping registered share...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124964143","title":"XUANZHUBIO-B gains NMPA NDA acceptance for Anaprazole Sodium to treat reflux esophagitis","url":"https://stock-news.laohu8.com/highlight/detail?id=1124964143","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124964143?lang=en_us&edition=fundamental","pubTime":"2026-06-30 12:43","pubTimestamp":1782794605,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharmaceutical Co., Ltd. (XUANZHUBIO-B) has received formal acceptance from China’s National Medical Products Administration (NMPA) for its New Drug Application covering a new...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647581790","title":"Xuanzhu Biopharma Says NMPA Accepts NDA for Anaprazole Sodium in Reflux Esophagitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2647581790","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647581790?lang=en_us&edition=fundamental","pubTime":"2026-06-30 12:05","pubTimestamp":1782792352,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharma says NMPA accepts NDA for anaprazole sodium in reflux esophagitisXuanzhu Biopharmaceutical’s NMPA accepted an NDA for anaprazole sodium enteric-coated tablets to treat adult reflux e","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260630:nNDL2BC18W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1593","BK1600","BK1191","BK1515","00460","02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647736581","title":"Xuanzhu Biopharmaceutical Co - Nmpa Accepts Nda for Anaprazole Sodium for Reflux Esophagitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2647736581","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647736581?lang=en_us&edition=fundamental","pubTime":"2026-06-30 12:05","pubTimestamp":1782792343,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260630:nFWN43116P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1191","02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647581738","title":"Xuanzhu Biopharmaceutical Co - Phase Iii Trial for Anaprazole Sodium Met Primary Endpoint with 88.4% Healing Rate","url":"https://stock-news.laohu8.com/highlight/detail?id=2647581738","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647581738?lang=en_us&edition=fundamental","pubTime":"2026-06-30 12:05","pubTimestamp":1782792343,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260630:nFWN43116P:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1191","02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645604874","title":"Xuanzhu Biopharmaceutical Enrolls First Patient in Anaprazole Sodium Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2645604874","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645604874?lang=en_us&edition=fundamental","pubTime":"2026-06-22 11:47","pubTimestamp":1782100063,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharmaceutical  enrolled the first patient in the phase 3 study of its stomach-acid drug anaprazole sodium, according to a Sunday filing with the Hong Kong bourse.The firm plans to study the drug as a treatment for Helicobacter pylori, a common bacterial infection linked to ulcers, gastritis, and gastric cancer.The study will enroll 556 adults, and if successful, will help expand the treatment's approval from its current indication of duodenal ulcer.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02575","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168313115","title":"Four Hong Kong-listed Companies Launch IPO Processes, Including Medical Robotics Firm, While Able Digital Inks Major Partnership with Alibaba Cloud","url":"https://stock-news.laohu8.com/highlight/detail?id=1168313115","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168313115?lang=en_us&edition=fundamental","pubTime":"2026-06-22 09:07","pubTimestamp":1782090474,"startTime":"0","endTime":"0","summary":"Several significant corporate developments have been announced in the Hong Kong market, covering new share offerings, strategic partnerships, and investment activities. Key Corporate Actions The...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1558","BK1191","02575","LU1023057109.AUD","BK1228","02687","BK1216","LU0067412154.USD","BK1554","01798","02657","LU1807302812.USD","03952","LU1960683339.HKD","01250","BK1594","LU1008478684.HKD","BK1610","BK1560","06936","06915","LU1152091754.HKD","BK1207","002352","LU0359201885.HKD","02697","LU1993786604.SGD","LU2213484517.USD","BK1154","06887","SCGEY","BK1116","06715","02558","BK1151","LU0880133367.SGD","03750","LU0359202008.SGD","300750","BK1235","LU0359201612.USD","00697","LU1152091168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122383034","title":"Xuanzhu Bio-B Initiates Phase III Trial for H. Pylori Eradication with New Anaprazole Sodium Indication","url":"https://stock-news.laohu8.com/highlight/detail?id=1122383034","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1122383034?lang=en_us&edition=fundamental","pubTime":"2026-06-21 18:14","pubTimestamp":1782036871,"startTime":"0","endTime":"0","summary":"Xuanzhu Bio-B (02575) has announced that its self-developed innovative drug, Anaprazole Sodium Enteric-coated Tablets (brand name: Anjiuwei®), has successfully enrolled the first patient into a Phase...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575","BK4134","BK1191","III"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645628097","title":"Xuanzhu Biopharma enrolls first patient in Phase III trial of anaprazole sodium for H. pylori eradication","url":"https://stock-news.laohu8.com/highlight/detail?id=2645628097","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645628097?lang=en_us&edition=fundamental","pubTime":"2026-06-21 18:05","pubTimestamp":1782036350,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharmaceutical enrolled the first patient in a Phase III trial of anaprazole sodium in Helicobacter pylori eradication therapy.Trial results have not been presented; the study will assess whether the regimen can clear infection safely versus an esomeprazole-based comparator.The study targets 556 adults across multiple centers with a 14-day treatment course.Anaprazole sodium is already marketed in China for duodenal ulcer; success could broaden its label and support faster commercial uptake.The company cited China’s H. pylori drug market at RMB 5.5 billion in 2024, projecting RMB 6.8 billion in 2029.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xuanzhu Biopharmaceutical Co. Ltd. published the original content used to genera","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260621:nNDL8bPT69:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK1191","02575","BK1593","00460","BK1600"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188910815","title":"XUANZHUBIO-B Announces Election of Employee Representative Director","url":"https://stock-news.laohu8.com/highlight/detail?id=1188910815","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188910815?lang=en_us&edition=fundamental","pubTime":"2026-06-18 18:28","pubTimestamp":1781778509,"startTime":"0","endTime":"0","summary":"XUANZHUBIO-B (02575) has issued a formal announcement regarding a board appointment.The company's employee representative congress convened on June 18, 2026.During the meeting, Ms. Yue Xin was...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153865036","title":"Xuanzhu Biopharmaceutical Tightens Governance Framework in Revised Articles; Confirms 9-Member Board and HK$517.95 Million Share Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=1153865036","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1153865036?lang=en_us&edition=fundamental","pubTime":"2026-06-18 18:25","pubTimestamp":1781778348,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharmaceutical Co., Ltd. (Xuanzhu Biopharmaceutical) has released its revised Articles of Association (effective June 2026), detailing updated corporate governance structures, capital...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644702139","title":"Xuanzhu Biopharmaceutical files director list with Hong Kong Stock Exchange","url":"https://stock-news.laohu8.com/highlight/detail?id=2644702139","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644702139?lang=en_us&edition=fundamental","pubTime":"2026-06-18 18:25","pubTimestamp":1781778311,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharmaceutical filed an updated list of directors with the Hong Kong Stock Exchange on June 18, 2026.Xu Yanjun remains chairperson of the board, also serving as general manager.The board comprises executive, non-executive, employee representative, and independent non-executive directors; key committee chairs are held by independent directors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xuanzhu Biopharmaceutical Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange  , on June 18, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260618:nNDLbTRqvN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575","BK1600","00460","BK1593","BK1515","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644611702","title":"Xuanzhu Biopharma names Yue Xin employee representative director after election","url":"https://stock-news.laohu8.com/highlight/detail?id=2644611702","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644611702?lang=en_us&edition=fundamental","pubTime":"2026-06-18 18:21","pubTimestamp":1781778080,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharmaceutical named Yue Xin as employee representative director, effective June 18, 2026.Yue replaces an executive director seat as the board shifts its composition.Li Jia Kui’s resignation as executive director takes effect immediately on Yue’s appointment.Yue served as a company supervisor from November 2021 to June 2026.She joined the group in 2019, rising from administrative assistant to head of administration.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xuanzhu Biopharmaceutical Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange  , on June 18, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260618:nNDLbVnXtt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1600","BK1515","00460","BK1191","02575","BK1593"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147854758","title":"Xuanzhu Bio Converts 357.25 Million Unlisted Shares to H Shares, Expanding Total Issued Capital to 517.95 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1147854758","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1147854758?lang=en_us&edition=fundamental","pubTime":"2026-06-04 19:03","pubTimestamp":1780571015,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharmaceutical Co., Ltd. (Xuanzhu Bio) disclosed its Monthly Return for Equity Issuer for the period ended 31 May 2026, highlighting a substantial restructuring of its share structure...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173805012","title":"XUANZHUBIO-B Shares Surge as Three Key Products Advance to Commercial Stage","url":"https://stock-news.laohu8.com/highlight/detail?id=1173805012","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173805012?lang=en_us&edition=fundamental","pubTime":"2026-06-04 14:50","pubTimestamp":1780555828,"startTime":"0","endTime":"0","summary":"Shares of XUANZHUBIO-B (02575) rose more than 5% in trading. At the time of writing, the stock was up 5.17% to HK$17.29, with a turnover of HK$46.84 million. Key Drivers Behind the Move A recent...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575","BK4585","BK4588","BK1191","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123331571","title":"Xuanzhu Biopharma to Seek Shareholder Nod on 2025 Reports, Profit Distribution and Board Mandates at 18 June 2026 AGM","url":"https://stock-news.laohu8.com/highlight/detail?id=1123331571","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123331571?lang=en_us&edition=fundamental","pubTime":"2026-05-27 17:04","pubTimestamp":1779872659,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharmaceutical Co., Ltd. (Xuanzhu Biopharma) has issued the proxy form and agenda for its annual general meeting scheduled for 10:30 a.m. on Thursday, 18 June 2026 at the Jing Tai Lan...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638080355","title":"Xuanzhu Biopharmaceutical announces annual general meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2638080355","media":"Reuters","labels":["conferences","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638080355?lang=en_us&edition=fundamental","pubTime":"2026-05-27 16:52","pubTimestamp":1779871976,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharmaceutical will hold its 2025 annual general meeting in Beijing on June 18, 2026.Shareholders will vote on the 2025 annual report package, including the board report, supervisory committee report, audited consolidated financial statements.A profit distribution plan will be tabled, with the board not recommending a final dividend for 2025.Items include a directors’ remuneration plan, reappointment of Ernst & Young as 2026 auditor, estimated audit fee RMB 2 million.Special resolutions cover mandates to repurchase up to 10% of issued H shares, issue up to 20%, abolish the supervisory committee, amend the articles.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xuanzhu Biopharmaceutical Co. Ltd. published the original conten","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nNDL5RwMrH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1600","02575","BK1191","BK1593","00460","BK1515"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":1,"totalSize":83,"code":"91000000","status":"200"}]}}